Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging combo could outsmart aggressive brain cancer

NCT ID NCT06466031

Knowledge-focused Sponsor: Copernicus Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a special PET scan (FET-PET) to standard MRI can better guide surgery and radiation for glioblastoma, the most aggressive brain tumor. About 189 adults with a single tumor will be randomly assigned to have treatment planning based on MRI alone or MRI plus FET-PET. The goal is to see if the combined imaging helps remove more active tumor tissue and delays regrowth, potentially improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 189 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Single macroscopic tumor focus with the appearance of glioblastoma multiforme on MRI with contrast - contrast-enhancing lesion, completely or with central necrosis, with surrounding edema. * No history of cancer in other organs. No suspicious lesions on X-ray of the chest and abdomen (CT with contrast). * No clinical suspicion of brain abscess - no meningeal symptoms, signs of neuroinfection, fever, elevated inflammatory parameters. * Primary tumor, without neurosurgical, radiotherapy or oncology intervention. Prior tumor biopsy is allowed. * Tumor eligible for surgical treatment - craniotomy and tumor resection. * Age ≥ 18 years but \< 70 years old. * Quality of life assessment: KPS ≥ 70. * Informed patient consent to the study and proposed treatment. * No allergy to contrast agents used in PET and MRI. * No medical contraindications to neurosurgery - craniotomy and resection. Exclusion Criteria: * Multifocal brain tumor. * Recurrence of glioblastoma multiforme. * Clinical or radiological suspicion of brain metastasis or brain abscess. * Postoperative histopathological diagnosis other than WHO grade IV glioblastoma. * Medical contraindications to any surgery under general anesthesia. * Pregnancy, breastfeeding. * Known allergy to gadolinium contrast or radiopharmaceutical tracing agent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma multiforme are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma multiforme

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Copernicus Memorial Hospital in Łódź, Poland

    RECRUITING

    Lodz, Łódź Voivodeship, 93-513, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.